| Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity WS Lee, H Yang, HJ Chon, C Kim Experimental & molecular medicine 52 (9), 1475-1485, 2020 | 371 | 2020 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 223 | 2023 |
| STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade H Yang, WS Lee, SJ Kong, CG Kim, JH Kim, SK Chang, S Kim, G Kim, ... The Journal of clinical investigation 129 (10), 4350-4364, 2019 | 201 | 2019 |
| Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma C Kim, EK Kim, H Jung, HJ Chon, JW Han, KH Shin, H Hu, KS Kim, ... BMC cancer 16, 1-7, 2016 | 155 | 2016 |
| Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia HJ Chon, WJ Hyung, C Kim, S Park, JH Kim, CH Park, JB Ahn, H Kim, ... Annals of surgery 265 (5), 946-953, 2017 | 149 | 2017 |
| Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma CG Kim, C Kim, SE Yoon, KH Kim, SJ Choi, B Kang, HR Kim, SH Park, ... Journal of hepatology 74 (2), 350-359, 2021 | 148 | 2021 |
| Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade HJ Chon, WS Lee, H Yang, SJ Kong, NK Lee, ES Moon, J Choi, EC Han, ... Clinical Cancer Research 25 (5), 1612-1623, 2019 | 138 | 2019 |
| Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea MH Hong, HS Kim, C Kim, JR Ahn, HJ Chon, SJ Shin, JB Ahn, HC Chung, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2009 | 83 | 2009 |
| Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ... ESMO open 7 (6), 100591, 2022 | 63 | 2022 |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label … S Qin, M Chen, AL Cheng, AO Kaseb, M Kudo, HC Lee, AC Yopp, J Zhou, ... The Lancet 402 (10415), 1835-1847, 2023 | 62 | 2023 |
| Clinical value of ezrin expression in primary osteosarcoma C Kim, E Shin, S Hong, HJ Chon, HR Kim, JR Ahn, MH Hong, WI Yang, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2009 | 62 | 2009 |
| Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients SM Lim, YN Kim, KH Park, B Kang, HJ Chon, C Kim, JH Kim, SY Rha BMC cancer 16, 1-7, 2016 | 61 | 2016 |
| STING signaling is a potential immunotherapeutic target in colorectal cancer HJ Chon, H Kim, JH Noh, H Yang, WS Lee, SJ Kong, SJ Lee, YS Lee, ... Journal of Cancer 10 (20), 4932, 2019 | 60 | 2019 |
| STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer SJ Lee, H Yang, WR Kim, YS Lee, WS Lee, SJ Kong, HJ Lee, JH Kim, ... Journal for Immunotherapy of Cancer 9 (6), 2021 | 55 | 2021 |
| Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer C Kim, HJ Chon, B Kang, K Kim, HC Jeung, HC Chung, SH Noh, SY Rha BMC cancer 13, 1-7, 2013 | 54 | 2013 |
| Peripheral blood-based biomarkers for immune checkpoint inhibitors HJ An, HJ Chon, C Kim International journal of molecular sciences 22 (17), 9414, 2021 | 53 | 2021 |
| Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ... European Journal of Cancer 175, 204-213, 2022 | 52 | 2022 |
| Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population A Casadei-Gardini, M Rimini, T Tada, G Suda, S Shimose, M Kudo, ... European Journal of Cancer 180, 9-20, 2023 | 51 | 2023 |
| Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma J Cheon, C Yoo, JY Hong, HS Kim, DW Lee, MA Lee, JW Kim, I Kim, ... Liver International 42 (3), 674-681, 2022 | 49 | 2022 |
| Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis J Cheon, HJ Chon, Y Bang, NH Park, JW Shin, KM Kim, HC Lee, J Lee, ... Liver Cancer 9 (5), 613-624, 2020 | 49 | 2020 |
Chan KimMedical Oncology, CHA Bundang Medical CenterVerified email at cha.ac.kr
